Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy.

Published

Journal Article

PURPOSE: To determine pretreatment prostate-specific antigen doubling times (PSADT) in patients referred for definitive radiotherapy. METHODS AND MATERIALS: One hundred and seven patients with histologically proven nonmetastatic prostate cancer and an elevated prostate-specific antigen (PSA) who were referred for radiation therapy had three serum PSA values obtained prior to the start of definitive therapy. Prostate-specific antigen doubling times were calculated by linear regression. RESULTS: Prostate-specific antigen values increased during the period of observation in 78 patients (73%). Forty-three patients (40%) had calculated PSADT of less than 2 years and of those patients with pretreatment serum PSA values of greater than 10 ng/mL more than 50% has calculated PSADT of less than 2 years. CONCLUSIONS: A significant minority of patients referred for radiotherapy have calculated PSADT of less than 2 years. The significance of this relatively fast growth rate is as yet undetermined, but suggests that patients referred for radiotherapy may have aggressive disease prior to treatment.

Full Text

Duke Authors

Cited Authors

  • Lee, WR; Hanks, GE; Corn, BW; Schultheiss, TE

Published Date

  • January 1, 1995

Published In

Volume / Issue

  • 31 / 1

Start / End Page

  • 21 - 24

PubMed ID

  • 7527798

Pubmed Central ID

  • 7527798

International Standard Serial Number (ISSN)

  • 0360-3016

Digital Object Identifier (DOI)

  • 10.1016/0360-3016(94)00339-M

Language

  • eng

Conference Location

  • United States